Literature DB >> 28143711

Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature.

Lindsay Wilde1, Siraj M Ali2, Charalambos C Solomides3, Jeffrey S Ross2, Edouard Trabulsi4, Jean Hoffman-Censits5.   

Abstract

Entities:  

Keywords:  Genomic profiling; Immunotherapy; PD-1 inhibitor; Small-cell carcinoma of the bladder; Variant histology

Mesh：

Substances：

Year:  2016        PMID： 28143711     DOI： 10.1016/j.clgc.2016.12.012

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  7 in total

1.  Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab.

Authors:  Tomoya Hatayama; Tetsutaro Hayashi; Shinji Matsuzaki; Hiroshi Masumoto; Hiroyuki Yanai; Hamidreza Abdi; Jun Teishima; Yasuhisa Hasegawa
Journal:  IJU Case Rep       Date:  2020-08-05

2.  Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.

Authors:  Natalie J Miller; Ali Raza Khaki; Leonidas N Diamantopoulos; Mehmet A Bilen; Victor Santos; Neeraj Agarwal; Rafael Morales-Barrera; Michael Devitt; Ariel Nelson; Christopher J Hoimes; Evan Shreck; Hussein Assi; Benjamin A Gartrell; Alex Sankin; Alejo Rodriguez-Vida; Mark Lythgoe; David J Pinato; Alexandra Drakaki; Monika Joshi; Pedro Isaacsson Velho; Noah Hahn; Sandy Liu; Lucia Alonso Buznego; Ignacio Duran; Marcus Moses; Jayanshu Jain; Jure Murgic; Pedro Barata; Abhishek Tripathi; Yousef Zakharia; Matthew D Galsky; Guru Sonpavde; Evan Y Yu; Gary H Lyman; Petros Grivas
Journal:  J Urol       Date:  2020-01-23       Impact factor: 7.450

3.  p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma.

Authors:  Borivoj Golijanin; Boris Gershman; Andre De Souza; Ohad Kott; Benedito A Carneiro; Anthony Mega; Dragan J Golijanin; Ali Amin
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

4.  Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience.

Authors:  Jean Hoffman-Censits; Woonyoung Choi; Trinity J Bivalacqua; Philip Pierorazio; Max Kates; Kara Lombardo; Vamsi Parini; David McConkey; Edouard J Trabulsi; Noah Hahn; Andres Matoso
Journal:  Clin Genitourin Cancer       Date:  2020-11-12       Impact factor: 3.121

5.  Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.

Authors:  Tim Mandelkow; Niclas C Blessin; Eva Lueerss; Laura Pott; Ronald Simon; Wenchao Li; Björn Wellge; Nicolaus F Debatin; Doris Höflmayer; Jakob R Izbicki; Franziska Büscheck; Andreas M Luebke; Corinna Wittmer; Frank Jacobsen; Florian Lutz; Eike Burandt; Stefan Steurer; Guido Sauter; Maria Christina Tsourlakis; Waldemar Wilczak; Andrea Hinsch; Sarah Minner
Journal:  Dis Markers       Date:  2019-05-02       Impact factor: 3.434

6.  A Case of Bladder Large Cell Carcinoma with Review of the Literature.

Authors:  Paolo Lopedote; Amir Yosef; Olga Kozyreva
Journal:  Case Rep Oncol       Date:  2022-03-29

7.  PD-1 Expression Status on CD8+ Tumour Infiltrating Lymphocytes Associates With Survival in Cervical Cancer.

Authors:  Peiwen Fan; Xi Li; Yaning Feng; Hongchao Cai; Danning Dong; Yanchun Peng; Xuan Yao; Yuping Guo; Miaomiao Ma; Tao Dong; Ruozheng Wang
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.